Sernova Corp.

Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22

Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update

Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications

Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med

Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions

Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes

Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences

Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy

Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes

Sernova Announces CEO Succession Plan and Expanded Management Team

Sernova Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Sernova to Present at Global Partnership Family Office – HealthCare & Biotechnology TSX Showcase

Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders